טוען...
Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy
Many potentially therapeutic molecules have been identified for treating Duchenne muscular dystrophy. However, targeting those molecules only to sites of active pathology is an obstacle to their clinical use. Because dystrophic muscles become extensively inflamed, we tested whether expressing a ther...
שמור ב:
| הוצא לאור ב: | Nat Commun |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group UK
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594976/ https://ncbi.nlm.nih.gov/pubmed/31243277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-10614-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|